Literature DB >> 35594368

Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor.

Katsuhiko Mitachi1, David Mingle1, Wendy Effah2, Antonio Sánchez-Ruiz3, Kirk E Hevener1, Ramesh Narayanan2, William M Clemons4, Francisco Sarabia5, Michio Kurosu1.   

Abstract

A short total synthesis of tunicamycin V (1), a non-selective phosphotransferase inhibitor, is achieved via a Büchner-Curtius-Schlotterbeck type reaction. Tunicamycin V can be synthesized in 15 chemical steps from D-galactal with 21 % overall yield. The established synthetic scheme is operationally very simple and flexible to introduce building blocks of interest. The inhibitory activity of one of the designed analogues 28 against human dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (DPAGT1) is 12.5 times greater than 1. While tunicamycins are cytotoxic molecules with a low selectivity, the novel analogue 28 displays selective cytostatic activity against breast cancer cell lines including a triple-negative breast cancer.
© 2022 Wiley-VCH GmbH.

Entities:  

Keywords:  Antimigration Effect; Cytostatic Activity; DPAGT1 Inhibitors; Total Synthesis; Tunicamycins

Mesh:

Substances:

Year:  2022        PMID: 35594368      PMCID: PMC9329268          DOI: 10.1002/anie.202203225

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   16.823


  48 in total

1.  Tunicamycin-induced endoplasmic reticulum stress reduces in vitro subpopulation and invasion of CD44+/CD24- phenotype breast cancer stem cells.

Authors:  Babak Nami; Huseyin Donmez; Nadir Kocak
Journal:  Exp Toxicol Pathol       Date:  2016-06-24

2.  Stereoselective syntheses of the O,N-protected subunits of the tunicamycins.

Authors:  W Karpiesiuk; A Banaszek
Journal:  Carbohydr Res       Date:  1997-04-30       Impact factor: 2.104

3.  Inhibition of N-Glycosylation towards Novel Anti-Cancer Chemotherapeutics.

Authors:  Michio Kurosu
Journal:  J Mol Pharm Org Process Res       Date:  2018-01-12

Review 4.  Thioglycosides in sequential glycosylation strategies.

Authors:  Jeroen D C Codée; Remy E J N Litjens; Leendert J van den Bos; Herman S Overkleeft; Gijsbert A van der Marel
Journal:  Chem Soc Rev       Date:  2005-07-27       Impact factor: 54.564

5.  Concise synthesis of capuramycin.

Authors:  Michio Kurosu; Kai Li; Dean C Crick
Journal:  Org Lett       Date:  2009-06-04       Impact factor: 6.005

6.  Biochemical effects and therapeutic potential of tunicamycin in murine L1210 leukemia.

Authors:  M J Morin; R J Bernacki
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

7.  Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.

Authors:  Helei Hou; Hefen Sun; Ping Lu; Chao Ge; Lixing Zhang; Hong Li; Fangyu Zhao; Hua Tian; Lin Zhang; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  Mol Cancer Ther       Date:  2013-10-15       Impact factor: 6.261

8.  Novel FR-900493 Analogues That Inhibit the Outgrowth of Clostridium difficile Spores.

Authors:  Katsuhiko Mitachi; Hyun Gi Yun; Sara M Kurosu; Shakiba Eslamimehr; Maddie R Lemieux; Lada Klaić; William M Clemons; Michio Kurosu
Journal:  ACS Omega       Date:  2018-02-09

9.  miR-770-5p regulates EMT and invasion in TNBC cells by targeting DNMT3A.

Authors:  Senem Noyan; Ayşe Andac Ozketen; Hakan Gurdal; Bala Gur Dedeoglu
Journal:  Cell Signal       Date:  2021-03-31       Impact factor: 4.315

10.  GlcNAc-1-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation.

Authors:  Jiho Yoo; Ellene H Mashalidis; Alvin C Y Kuk; Kazuki Yamamoto; Benjamin Kaeser; Satoshi Ichikawa; Seok-Yong Lee
Journal:  Nat Struct Mol Biol       Date:  2018-02-19       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.